Kymera Therapeutics
KYMR
275 hedge funds and large institutions have $11.1B invested in Kymera Therapeutics in 2026 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 96 increasing their positions, 84 reducing their positions, and 26 closing their positions.
85% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 26
44% more call options, than puts
Call options by funds: $58.8M | Put options by funds: $40.8M
38% more capital invested
Capital invested by funds: $8.01B → $11.1B (+$3.08B)
14% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 84
7% more funds holding
Funds holding: 256 → 275 (+19)
14% less funds holding in top 10
Funds holding in top 10: 14 → 12 (-2)
188.88% less ownership
Funds ownership: 306.81% → 117.92% (-189%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$90.4M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$68.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$55.8M |
| 4 |
BlackRock
New York
|
+$41M |
| 5 |
State Street
Boston,
Massachusetts
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$149M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$140M |
| 3 |
DM
Deerfield Management
New York
|
-$46.7M |
| 4 |
CC
Commodore Capital
New York
|
-$43M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$24.4M |
KYMR Hedge Fund Activity: Q2 2026 in Review
275 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q2 2026, worth a combined $11.1B — up 38% from $8.01B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new KYMR positions and 26 closed out — a net gain of 22 holders — while 96 added to existing stakes and 84 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $90.4M. The largest seller was Atlas Venture Life Science Advisors, cutting an estimated $149M.
- 275 institutional investors held Kymera Therapeutics (KYMR) as of Q2 2026, up from 256 in Q1 2026.
- Funds reported $11.1B of Kymera Therapeutics stock for Q2 2026, up 38% quarter-over-quarter.
- 48 funds opened new Kymera Therapeutics positions in Q2 2026 and 26 closed out, a net change of +22 holders.
- The largest Kymera Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $90.4M added.
- The largest Kymera Therapeutics seller in Q2 2026 was Atlas Venture Life Science Advisors, an estimated $149M sold.
Based on aggregated 13F filings for Q2 2026.